Treatment of Psychosis and Agitation in Alzheimer's Disease
Information source: New York State Psychiatric Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer's Disease; Psychosis; Agitation
Intervention: Lithium (Drug); Placebo (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: New York State Psychiatric Institute Official(s) and/or principal investigator(s): DP Devanand, MD, Principal Investigator, Affiliation: Columbia University
Overall contact: DP Devanand, MD, Phone: 646 774 8658, Ext: 8658, Email: dpd3@columbia.edu
Summary
Clinically, many patients with AD show no response or minimal response to antipsychotics for
symptoms of agitation/aggression or psychosis, or they have intolerable side effects on
these medications. Antipsychotics have a wide range of side effects, including the risk of
increased mortality (60-70% higher rate of death on antipsychotic compared to placebo) that
led to an FDA black box warning for patients with dementia; a more recent review and
meta-analysis showed a 54% increased risk of mortality. In addition, some patients show
only partial response to antipsychotics and symptoms persist. For these reasons, the
investigators need to study alternative treatment strategies. Currently, there is no
FDA-approved medication for the treatment of psychosis or agitation in AD.
The investigators innovative project will examine the efficacy and side effects of low dose
lithium treatment of agitation/aggression with or without psychosis in 80 patients with AD
in a randomized, doubleblind, placebo-controlled, 12-week trial (essentially a Phase II
trial). The results will determine the potential for a large-scale clinical trial (Phase
III) to establish the utility of lithium in these patients.
Clinical Details
Official title: Treatment of Psychosis and Agitation in Alzheimer's Disease
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Change in Neuropsychiatric Inventory (NPI) Score
Secondary outcome: Clinical Global Impression (CGI) GlobalClinical Global Impression (CGI) Behavior Young Mania Rating Scale Treatment Emergent Signs and Symptoms (TESS) Simpson-Angus Scale Basic Activities of Daily Living (BADL) Zarit Caregiver Burden Interview Clinical Dementia Rating Scale (CDR)
Detailed description:
Symptoms of psychosis or agitation are common in Alzheimer's disease. These symptoms are
associated with distress for the patient, an increased burden for caregivers, more rapid
cognitive decline, greater risk of institutionalization and mortality, and increased health
care costs. In a recent meta-analysis, caregiver education and behavior modification studies
revealed a small to medium effect size in treating agitation in these patients. However,
none of these studies were double-blind (difficult to achieve in such studies) and none had
a control group that received the same amount of staff time as the intervention group,
thereby biasing the results toward the active intervention.
Among the psychotropic medications that have been studied, only antipsychotics have shown
superiority over placebo for the treatment of psychosis and agitation in patients with
dementia.
However, most studies show only moderate superiority for antipsychotic over placebo and a
few studies have been negative. The side effects of antipsychotic medications include
sedation, extrapyramidal signs, tardive dyskinesia, weight gain, and the metabolic syndrome.
A pooled analysis from 17 short-term trials showed that the mortality rate in patients with
dementia receiving antipsychotic medications was 1. 6 to 1. 7 times as high (60-70% increase
in mortality rate) as the mortality rate in patients receiving placebo. These findings led
the FDA to issue a black-box warning for antipsychotic medication use in patients with
dementia; a more recent meta-analysis reported a slightly lower odds ratio of 1. 54 (54%
increase in mortality rate).
Lithium has several different actions from anticonvulsants, though both are effective in
bipolar disorder, especially mania. Lithium is not being proposed here to treat mania in AD
though the investigators will monitor symptoms on the Young Mania Rating Scale. In patients
with AD, lithium has been studied for its putative cognitive enhancing effects. A few
reports suggest that chronic lithium use reduces the risk of dementia, but other data show
increased dementia risk with lithium use. A placebo-controlled, single-blind lithium trial
showed no cognitive effects in patients with AD, but a recent trial of lithium in 45
patients with mild cognitive impairment (MCI, which often leads to clinically diagnosable
AD) showed a small advantage for lithium (n=24) over placebo (n=21) in attention and other
cognitive domains. None of these studies with lithium were intended to treat psychosis or
agitation in AD, and patients with these symptoms typically were excluded in these clinical
trials.
There has been no systematic placebo-controlled trial of lithium to treat
agitation/aggression with or without psychosis in AD even though lithium is a highly
effective treatment for mania with psychosis and symptoms of agitation or aggression.
Nonetheless, the published studies of lithium to treat cognitive decline in older patients
show that low-dose lithium is safe in patients with MCI or AD.
Specific Aims and Hypotheses Specific Aim 1. To compare changes in agitation/aggression with
or without psychosis in patients with AD who receive 12 weeks of randomized, double-blind
treatment with lithium or placebo.
Primary Hypothesis. Over these 12 weeks, the agitation/aggression domain score on the
Neuropsychiatric Inventory (NPI) will decrease significantly more on lithium than placebo.
Secondary Hypothesis. Over these 12 weeks, the proportion of responders on lithium will be
significantly greater than the proportion of responders on placebo. Response is defined as a
30% decrease in NPI core score (defined as the sum of domains for agitation/aggression,
delusions and hallucinations) plus a CGI Change score of much improved or very much improved
(CGI based on these behavioral symptoms only). Exploratory hypothesis. Over these 12 weeks,
the psychosis score, measured by the sum of the NPI domain scores for delusions and
hallucinations, will decrease significantly more on lithium than placebo. Specific Aim 2. To
evaluate the tolerability of low dose lithium by assessing emergent somatic side effects
over the course of the 12-week trial on lithium compared to placebo. Specific Aim 3. To
explore associations between improvement on lithium (decrease in agitation/aggression and
psychosis scores) and serum brain-derived neurotrophic factor (BDNF) levels (baseline, 12
weeks), a SNP in intron 1 of the ACCN1 gene, and variation at the 7q11. 2 gene locus, because
these indices are associated with lithium response in bipolar disorder. The investigators do
not postulate a specific mechanism of action for lithium in the investigators trial, but
will evaluate these three potential predictors of lithium response with the aim of improving
patient selection for personalized treatment. The investigators will examine BDNF serum
levels as a biomarker correlate of lithium treatment by correlating change in BDNF levels
with change in NPI agitation/aggression and psychosis scores.
Eligibility
Minimum age: 55 Years.
Maximum age: 95 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Age 55-95 years
2. Diagnosis of possible or probable AD by standard NIA criteria (McKahnn et al, 1984;
McKhann et all, 2011)
3. Folstein MMSE 5-26 out of 30
4. Neuropsychiatric Inventory (NPI) agitation/aggression subscale score > 4. On each
subscale (frequency X severity), a score higher than 4 represents moderate to severe
symptoms.
5. Female patients need to be post-menopausal
6. Availability of informant; patients without an informant will not be recruited.
Patients who lack capacity must have a surrogate.
Exclusion Criteria:
1. Medical contraindication to lithium treatment or prior history of intolerability to
lithium treatment.
Contraindications to lithium in this study include: resting tremor causing functional
impairment, history of falls in the last month, untreated thyroid disease or any
abnormal thyroid function test (T3, T4, or TSH), creatinine level greater than 1. 5
mg/100ml or a glomerular filtration rate less than 44ml/min/ 1. 73m2; blood pressure >
150/90 mm Hg; heart rate < 50 bpm; unstable cardiac disease based on history,
physical examination, and ECG.
2. Medications, in combination with lithium, known to have adverse renal effects,
including therapeutic or higher doses of diuretics, i. e. hydrochlorothiazide greater
than 25mg daily or furosemide greater than 10mg daily. Whenever feasible, patients
receiving concomitant antidepressants or antipsychotics will be washed off these
medications for at least 24 hours before starting lithium. Patients who do not wish
to discontinue antipsychotics or antidepressants, typically because of family
member/caregiver objection, will be allowed to enter the trial provided there is no
contraindication to concomitant lithium use with that specific psychotropic
medication. During the trial, patients will be permitted to receive lorazepam as
needed up to 2 mg/day for anxiety/insomnia, and non-benzodiazepine hypnotics, e. g.,
zolpidem.
3. Current clinical diagnosis of schizophrenia, schizoaffective disorder, other
psychosis, or bipolar 1 disorder (DSM-IV TR criteria).
4. Current or recent (past 6 months) alcohol or substance dependence (DSM-IV TR
criteria).
5. Current major depression or suicidality as assessed by the study psychiatrist.
6. Suicidal behavior or dangerous behavior with serious safety risk or risk of physical
harm to self or others.
7. Parkinson's disease, Lewy body disease, multiple sclerosis, CNS infection,
Huntington's disease, amyotrophic lateral sclerosis, other major neurological
disorder.
8. Clinical stroke with residual neurological deficits. MRI findings of cerebrovascular
disease (smallinfarcts, lacunes, periventricular disease) in the absence of clinical
stroke with residual neurological deficits will not lead to exclusion.
9. Acute, severe, unstable medical illness. For cancer, patients with active illness or
metastases will be excluded, but past history of successfully treated cancer will not
lead to exclusion.
10. QTc interval > 460 ms at the time of baseline EKG is an exclusion criterion for
treatment.
Locations and Contacts
DP Devanand, MD, Phone: 646 774 8658, Ext: 8658, Email: dpd3@columbia.edu
New York State Psychiatric Institute, New York, New York 10032, United States; Recruiting Alla Malovichko, MA, Phone: 646-774-8668, Ext: 8668, Email: malovic@nyspi.columbia.edu DP Devanand, MD, Principal Investigator Gregory Pelton, MD, Sub-Investigator Edward Huey, MD, Sub-Investigator
Additional Information
Related publications: Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998 Nov;155(11):1512-20. Camins A, Verdaguer E, Junyent F, Yeste-Velasco M, Pelegrí C, Vilaplana J, Pallás M. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther. 2009 Winter;15(4):333-44. doi: 10.1111/j.1755-5949.2009.00086.x. Review. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058. Erratum in: N Engl J Med. 2012 Dec 20;367(25):2458. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):20-2. Fahy S, Lawlor BA. Lithium use in octogenarians. Int J Geriatr Psychiatry. 2001 Oct;16(10):1000-3. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011 May;198(5):351-6. doi: 10.1192/bjp.bp.110.080044. Haddad P, Wieck A, Yarrow M, Denham P. 1999. The Lithium Side Effects Rating Scale (LISERS); development of a self-rating instrument. Eur Neuropsychopharmacol 9(s5): 231-232. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009 Jun;70(6):922-31. Janowsky DS, Buneviciute J, Hu Q, Davis JM. Lithium-induced renal insufficiency: a longitudinal study of creatinine increases in intellectually disabled adults. J Clin Psychopharmacol. 2011 Dec;31(6):769-73. doi: 10.1097/JCP.0b013e31823607db. Jefferson JW. A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry. 2010 Sep;71(9):1153-7. doi: 10.4088/JCP.09m05917yel. Review. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May;22(5):475-84. Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008 Nov;65(11):1331-5. doi: 10.1001/archpsyc.65.11.1331. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry. 2008 Jul;23(7):704-11. doi: 10.1002/gps.1964. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012 Feb 25;379(9817):721-8. doi: 10.1016/S0140-6736(11)61516-X. Epub 2012 Jan 20. Review. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007 Apr;190:359-60. Rej S, Abitbol R, Looper K, Segal M. Chronic renal failure in lithium-using geriatric patients: effects of lithium continuation versus discontinuation--a 60-month retrospective study. Int J Geriatr Psychiatry. 2013 May;28(5):450-3. doi: 10.1002/gps.3841. Epub 2012 Jun 4. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934-43. Shulman KI, Sykora K, Gill SS, Mamdani M, Anderson G, Marras C, Wodchis WP, Lee PE, Rochon P. New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice. Am J Geriatr Psychiatry. 2005 Apr;13(4):299-304. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug;68(8):853-61. doi: 10.1001/archgenpsychiatry.2011.72. Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord. 2010 Nov;126(3):436-40. doi: 10.1016/j.jad.2010.04.018. Epub 2010 May 16. Wong YW, Tam S, So KF, Chen JY, Cheng WS, Luk KD, Tang SW, Young W. A three-month, open-label, single-arm trial evaluating the safety and pharmacokinetics of oral lithium in patients with chronic spinal cord injury. Spinal Cord. 2011 Jan;49(1):94-8. doi: 10.1038/sc.2010.69. Epub 2010 Jun 8. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2011;24(4):739-49. doi: 10.3233/JAD-2011-101875.
Starting date: June 2014
Last updated: April 14, 2015
|